Metadon Molteni (Methadone Hydrochloride)

Methadone Hydrochloride works by binding to mu‑opioid receptors in the central nervous system as a full agonist. This activation blocks pain signals and reduces the neuronal activity that drives opioid withdrawal, resulting in analgesia and stabilization of patients with opioid use disorder.

The appropriate dose of Metadon Molteni is individualized for each patient. A qualified prescriber determines the starting amount, titration schedule, and maintenance dose based on clinical assessment, treatment goals, and patient response. No fixed regimen is provided here.

Safety data for methadone use in pregnancy and lactation are limited. Methadone may be prescribed when the benefits outweigh potential risks, but clinicians must evaluate maternal health, fetal development, and neonatal outcomes. Breastfeeding decisions should be made in consultation with a healthcare professional.

To order Metadon Molteni, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both methadone (Metadon Molteni) and buprenorphine are used for opioid dependence, but methadone is a full mu‑opioid agonist offering stronger analgesia and a longer half‑life, while buprenorphine is a partial agonist with a ceiling effect that reduces overdose risk. Choice depends on patient history, treatment setting, and clinician judgment.

Metadon Molteni should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and excessive heat. Ensure the container is tightly closed to maintain stability.

Metadon Molteni is administered orally. The tablet or oral formulation should be swallowed whole with a full glass of water. It is not intended for crushing, chewing, or sublingual use, and dosing intervals are determined by the prescribing clinician.

The most serious risks include respiratory depression, which can be life‑threatening, especially when combined with other central nervous system depressants; QT interval prolongation, which may lead to cardiac arrhythmias; and severe hypotension. Patients should be monitored closely for these events, particularly during dose adjustments.

Metadon Molteni should be avoided in individuals with known hypersensitivity to methadone or any excipients, patients with severe respiratory depression, uncontrolled asthma, or acute pulmonary conditions, and those taking medications that significantly prolong the QT interval without appropriate monitoring. Contraindications must be confirmed by a qualified healthcare professional.